NSMCE2, a Novel Super-Enhancer-Regulated Gene, Is Linked to Poor Prognosis and Therapy Resistance in Breast Cancer

Researchers bioinformatically identified two novel super-enhancer-associated genes – NSMCE2 and MAL2. Through in-vitro pharmacological super-enhancer disruption assays, they confirmed that super-enhancers upregulate NSMCE2 and MAL2 transcriptionally.